血液疾病与输血杂志

抽象的

Risk of Haematologic Side Effects in Multiple Myeloma Patients Treated with Daratumumab

Wing Kit Lai, Denise E. Jackson*

Background: Daratumumab is a novel monoclonal antibody (anti-CD38) drug that mainly for multiple myeloma patients. Hematologic adverse events are the most common in daratumumab-treated patients. However, the odds of daratumumab inducing the side effects have inadequate publications to support. This systematic review and meta- analysis were to investigate the hematologic safety of daratumumab.

Methods: PubMed, EMBASE, Scopus, Cochrane library, Google Scholar were used for searching eligible clinical trials systematically from January 2010 to August 2021, only randomized case control trials were included.

Results: Nine studies were included in the meta-analysis. The use of daratumumab associated with a lower risk of anemia (Odd Ratio [OR], 0.83; 95% Confidence Interval [CI], 0.72-0.96; I2=0%; P=0.01) but a significantly higher risk of thrombocytopenia (OR, 1.34; 95% CI, 1.02-1.76; I2=71%; P=0.04), neutropenia (OR, 1.83; 95% CI, 1.42- 2.34; I2=70%; p<0.00001), and lymphopenia (OR, 1.53; 95% CI, 1.23-1.91; I2=21%; P=0.0002).

Conclusion: The administration of daratumumab increased the risk of thrombocytopenia, neutropenia, and lymphopenia in clinical trials, the risk of those events also increased. However, it showed a protective effect on anemia in clinical trials.